Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Roivant Sciences

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant Sciences Announces Proposed Public Offering of Common Shares
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
From Roivant Sciences
Via Globe NewsWire
Tickers PFE ROIV ROIVW
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant Sciences Announces Proposed Public Equity Offering
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
From Roivant Sciences
Via Globe NewsWire
Tickers ROIV ROIVW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.